NO337276B1 - Anvendelse av 10-propargyl-10-deazaaminopterin for fremstilling av et farmasøytisk middel for behandling av T-cellelymfom - Google Patents

Anvendelse av 10-propargyl-10-deazaaminopterin for fremstilling av et farmasøytisk middel for behandling av T-cellelymfom Download PDF

Info

Publication number
NO337276B1
NO337276B1 NO20065971A NO20065971A NO337276B1 NO 337276 B1 NO337276 B1 NO 337276B1 NO 20065971 A NO20065971 A NO 20065971A NO 20065971 A NO20065971 A NO 20065971A NO 337276 B1 NO337276 B1 NO 337276B1
Authority
NO
Norway
Prior art keywords
propargyl
deazaaminopterin
cell lymphoma
pdx
treatment
Prior art date
Application number
NO20065971A
Other languages
English (en)
Norwegian (no)
Other versions
NO20065971L (no
Inventor
Owen A O'conner
Francis Sirotnak
Original Assignee
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO337276(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer Res filed Critical Sloan Kettering Inst Cancer Res
Publication of NO20065971L publication Critical patent/NO20065971L/no
Publication of NO337276B1 publication Critical patent/NO337276B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20065971A 2004-05-30 2006-12-22 Anvendelse av 10-propargyl-10-deazaaminopterin for fremstilling av et farmasøytisk middel for behandling av T-cellelymfom NO337276B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
PCT/US2005/019169 WO2005117891A1 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Publications (2)

Publication Number Publication Date
NO20065971L NO20065971L (no) 2006-12-22
NO337276B1 true NO337276B1 (no) 2016-02-29

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065971A NO337276B1 (no) 2004-05-30 2006-12-22 Anvendelse av 10-propargyl-10-deazaaminopterin for fremstilling av et farmasøytisk middel for behandling av T-cellelymfom

Country Status (23)

Country Link
US (4) US7622470B2 (cg-RX-API-DMAC7.html)
EP (1) EP1750716B1 (cg-RX-API-DMAC7.html)
JP (1) JP5005532B2 (cg-RX-API-DMAC7.html)
KR (1) KR101189693B1 (cg-RX-API-DMAC7.html)
CN (2) CN1960734A (cg-RX-API-DMAC7.html)
AT (1) ATE405272T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005249516B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510895A (cg-RX-API-DMAC7.html)
CA (1) CA2565968C (cg-RX-API-DMAC7.html)
DE (1) DE602005009176D1 (cg-RX-API-DMAC7.html)
DK (1) DK1750716T3 (cg-RX-API-DMAC7.html)
ES (1) ES2313365T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20080569T3 (cg-RX-API-DMAC7.html)
ME (1) ME01087B (cg-RX-API-DMAC7.html)
MX (1) MXPA06013559A (cg-RX-API-DMAC7.html)
NO (1) NO337276B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ551082A (cg-RX-API-DMAC7.html)
PL (1) PL1750716T3 (cg-RX-API-DMAC7.html)
PT (1) PT1750716E (cg-RX-API-DMAC7.html)
RS (1) RS50622B (cg-RX-API-DMAC7.html)
SI (1) SI1750716T1 (cg-RX-API-DMAC7.html)
WO (2) WO2005117892A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609266B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
BRPI0510895A (pt) 2004-05-30 2007-11-27 Sloan Kettering Inst Cancer formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
EP2179284B1 (en) 2007-07-31 2016-09-28 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
WO2011096947A1 (en) * 2010-02-02 2011-08-11 Allos Therapeutics, Inc. Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same
AU2011261384B2 (en) * 2010-06-02 2015-01-22 Allos Therapeutics, Inc. Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
AU2011289638B2 (en) * 2010-08-10 2014-10-30 Allos Therapeutics, Inc. Methods for extending progression-free survival using 10-propargyl-10-deazaaminopterin
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
US11439643B2 (en) 2015-06-16 2022-09-13 Acrotech Biopharma Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
CA2055813A1 (en) * 1990-11-20 1992-05-21 Dariush Davalian Cyclosporin immunoassay
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6028071A (en) * 1996-07-17 2000-02-22 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
BRPI0510895A (pt) * 2004-05-30 2007-11-27 Sloan Kettering Inst Cancer formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WANG E S, ET AL.: "ACTIVITY OF A NOVEL ANTI-FOLATE (PDX, 10-PROPARGYL 10-DEAZAAMINOPTERIN) AGAINST HUMAN LYMPHOMA IS SUPERIOR TO METHOTREXATE AND CORRELATES WITH TUMOR RFC-1 GENE EXPRESSION", LEUKEMIA AND LYMPHOMA., INFORMA HEALTHCARE, US, vol. 44, no. 06, 1 June 2003 (2003-06-01), US, pages 1027 - 1035, XP009053320, ISSN: 1042-8194, DOI: 10.1080/1042819031000077124 *
WANG E S, ET AL.: "PDX, A NOVEL ANTIFOLATE WITH POTENT IN VITRO AND IN VIVO ACTIVITY IN NON-HODGKIN'S LYMPHOMA", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 11, PART 01, 16 November 2001 (2001-11-16), US, pages 612A, XP009053394, ISSN: 0006-4971, DOI: 10.1182/blood.V98.10.3113 *

Also Published As

Publication number Publication date
DE602005009176D1 (de) 2008-10-02
MXPA06013559A (es) 2007-04-24
SI1750716T1 (sl) 2009-06-30
ME01087B (me) 2012-12-20
WO2005117892A1 (en) 2005-12-15
NZ576849A (en) 2011-03-31
ES2313365T3 (es) 2009-03-01
US20050267117A1 (en) 2005-12-01
US7939530B2 (en) 2011-05-10
HRP20080569T3 (en) 2008-12-31
US20100120777A1 (en) 2010-05-13
ZA200609266B (en) 2008-12-31
RS50622B (sr) 2010-06-30
EP1750716A1 (en) 2007-02-14
PT1750716E (pt) 2008-11-04
US20080058280A1 (en) 2008-03-06
AU2005249516B2 (en) 2010-11-18
ATE405272T1 (de) 2008-09-15
PL1750716T3 (pl) 2009-01-30
DK1750716T3 (da) 2008-12-08
CN1960734A (zh) 2007-05-09
US8299078B2 (en) 2012-10-30
KR20110081327A (ko) 2011-07-13
US20130053391A1 (en) 2013-02-28
CN102824346A (zh) 2012-12-19
JP2008501038A (ja) 2008-01-17
HK1177901A1 (en) 2013-08-30
BRPI0510895A (pt) 2007-11-27
NZ551082A (en) 2009-06-26
WO2005117891A1 (en) 2005-12-15
JP5005532B2 (ja) 2012-08-22
KR101189693B1 (ko) 2012-10-10
EP1750716B1 (en) 2008-08-20
CA2565968C (en) 2013-01-08
US7622470B2 (en) 2009-11-24
AU2005249516A1 (en) 2005-12-15
CA2565968A1 (en) 2005-12-15
NO20065971L (no) 2006-12-22
CN102824346B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
US20130053391A1 (en) Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin
DK2575466T3 (en) Methods of treating methotrexate resistant disorders of 10-propargyl-10-deazaaminopterin
DK2531193T3 (en) Diastereomers of the 10-propargyl-10-deazaaminopterin FOR USE IN THE TREATMENT OF CANCER
US6323205B1 (en) Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
Hynes et al. Synthesis of 5-chloro-5, 8-dideaza analogs of folic acid and aminopterin targeted for colon adenocarcinoma
CN109846873B (zh) 一种抗肿瘤药物组合物
KR101189692B1 (ko) 10-프로파르질-10-데아자아미노프테린을 사용하는 t-세포림프종의 치료
HK1177901B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2023239821A2 (en) Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib
HK1179823B (en) Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
JPS6312845B2 (cg-RX-API-DMAC7.html)